Erl Wood, Alcobendas, San Diego, Imclone NYC Protein Palace--in that order. Rolling waves of layoffs/closures as the headcount cuts accelerate beyond 5500. "Unexpected" early patent losses/invalidations, more ligitation/fines, greater revenue loss...
Some of those let go by Leichleiter can go work for Jeffrey Immelt at GE. Now there is one smart CEO. He says that workers in 'other countries' do not have the same kind of quality output that American workers provide, so he creates 550 American jobs - and collects a large federal tax credit.
Now THAT is a CEO that has my vote, and the employees' vote, and the stockholder's vote and with that kind of combination of economic and political finesse, heck he could probably pick up the presidency of the US. Would you vote for him?
FIPNET calls for Everything except for senior management, the strategy group, and the board of directors to be owned and ran by a third party. It will cost Lilly a lot more money, but management and the BOD will all make a ton of money along the way.
Cut headcount. Cut salaries. All US and OUS global sites are on the block. No exceptions.
Senior management and strategy can be contracted out, too. All that will remain is the Board and the Brand. Expect corporation move to China to avoid US taxes. No one seems concerned about the risk to IP or patient privacy.
Take 1 shot Kentucky bourbon, 1 shot of tears from the 'reallocated and 1 shot of Ladie-Boiz'-drippings---shake and enjoy!
Seems like JCL and coterie is waist deep into buying the argument that antibody treatment for everything. Perhaps. More likely not, if you look at how data is interpreted. Idiot!
Most of you are missing the point. Sedgwick ran another group of researchers into the ground just as he did in Indianapolis. Think he'll be laid off? Ask anyone in his old DHT.